Panelists to Present Views on Emerging Strategies For Saving the Heart,
Including Medicure's Novel Approach to Cardioprotection
WINNIPEG, Manitoba - (September 13, 2004) -
Medicure Inc. (TSX:MPH/Amex:MCU), a cardiovascular drug discovery
and development company, is pleased to announce that it will host
a special Cardiovascular Symposium in New York City on October 13,
2004. Entitled "Emerging Strategies For Saving Your Heart",
the Symposium will feature four leading cardiovascular experts who
will discuss the need for novel therapies in the treatment of myocardial
ischemia, including the promise of Medicure's lead drug, MC-1.
The symposium will be chaired by respected cardiologist, Paul Armstrong,
MD, FRRCP(C), Professor of Medicine at the University of Alberta,
Past Member, FDA Cardio Renal Advisory Board, and Chair of Medicure's
Scientific Advisory Board. Dr. Armstrong will be joined by a distinguished
group of panelists, all leaders in the field of cardiovascular medicine:
· Roberto Bolli, MD, Professor of Medicine, Division of Cardiology,
and Director, Institute of Molecular Cardiology, University of Louisville;
· Christopher Granger, MD, Associate Professor of Medicine
and Director, Cardiac Care Unit, Duke University Medical Center;
and,
· Robert A. Harrington, MD, FACC, Professor of Medicine,
Duke University Medical Center and Director of Cardiovascular Clinical
Trials, Duke Clinical Research Institute.
"This symposium provides an excellent opportunity to hear
three leading experts, seasoned in the science and clinical treatment
of cardiovascular disease, address the serious medical repercussions
of acute coronary syndromes and their treatment," stated Dr.
Armstrong.
"In addition, the panelists will discuss the current state
of medicine in the field of cardiology, along with the future therapeutics,
with a particular focus on Medicure's novel approach to protecting
the ischemic myocardium," he added.
Commenting on the Company's involvement in presenting this symposium,
Medicure President and Chief Executive Office, Albert D. Friesen,
Ph.D. stated: "We are honoured to have four of North America's
foremost experts in the field of cardiovascular medicine participate
in this event. We believe this is an excellent opportunity to enhance
our shareholders' and the investment community's knowledge and understanding
of cardiovascular disease, and why it is so vital to develop novel
therapies like MC-1 to address the unmet needs in treating myocardial
ischemia."
Symposium Details
Date: Wednesday, October 13, 2004
Time: 4 pm Eastern Time
Location: New York City
Venue: The Four Seasons Hotel (Salon A & B), 57 East 57th Street
Webcast: Will be available at the Medicure website: www.medicureinc.com/symposium.htm.
Details to be provided at a later date.
Additional information, including the formal agenda and the topics
of discussion can be seen at either the Medicure website, or the
Trout Group website at www.troutgroup.com.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on reduction of damage associated with acute coronary
syndromes/acute myocardial infarction and cardiovascular interventions
such as angioplasty and Coronary Artery Bypass Graft (CABG). Medicure
is currently enrolling patients in its MEND-CABG clinical trial,
which will evaluate the cardioprotective and neuroprotective effects
of MC-1 in up to 900 patients undergoing high-risk CABG.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Don Bain
Director of Investor & Public Relations
Derek Reimer
Chief Financial Officer
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to 2004 News Archives
